Embargo will expire:22-Aug-2018 5:00 PM EDTReleased to reporters:20-Aug-2018 2:05 PM EDT |
|
Article ID: 699162 University of Colorado Cancer CenterDoctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening. |
Article ID: 698976 Fred Hutchinson Cancer Research CenterWhen enrolled in a cancer clinical trial, the differences in survival rates between rural and urban patients are significantly reduced, SWOG study results show. |
Embargo will expire:21-Aug-2018 11:00 AM EDTReleased to reporters:16-Aug-2018 2:00 PM EDT |
Article ID: 699109 Moffitt Cancer CenterA new study focusing on the environment inside cancer cells may lead to new targeted treatment strategies. Moffitt Cancer Center researchers, in collaboration with colleagues from the University of Maryland and the Institute for Research in Biomedicine Barcelona, suggest that lowering the pH inside cancer cells to make it more acidic can slow down the growth and spread of the disease, and possibly provide new options for treatment. |
|
Article ID: 699110 Rutgers Cancer Institute of New JerseyRutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as designated by the National Cancer Institute (NCI), has successfully renewed this designation. |
Article ID: 699077 Yale Cancer CenterYale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. |
Article ID: 699039 University of New Mexico Comprehensive Cancer CenterNeuroendocrine cancer is rare and hard to diagnose – and it can be difficult to treat and to survive. To help make more accurate diagnoses more quickly, the UNM Department of Radiology recently started using a new, injectable imaging agent to pinpoint neuroendocrine tumors. And in October, UNM Cancer Center will begin offering a new treatment that uses part of that imaging agent to fight the tumors. |
Article ID: 699023 University of Texas M. D. Anderson Cancer CenterIn a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. |
|
Article ID: 698978 Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center announced it received a five year Science Education Partnership Award (SEPA) from The National Institute of General Medical Sciences (NIGMS), worth $1.26 million. |